Optic Nerve Diseases
Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.
Subtype terms (9)
More specific conditions that are subtypes of Optic Nerve Diseases in the MeSH hierarchy.
- Low Tension Glaucoma
10 drugs (7 approved, 3 experimental)
- Optic Atrophy
12 drugs (6 approved, 6 experimental)
- Optic Disk Drusen
- Optic Nerve Hypoplasia
2 drugs (1 approved, 1 experimental)
- Optic Nerve Injuries
5 drugs (2 approved, 3 experimental)
- Optic Nerve Neoplasms
- Optic Neuritis
25 drugs (18 approved, 7 experimental)
- Optic Neuropathy, Ischemic
24 drugs (19 approved, 5 experimental)
- Papilledema
9 drugs (8 approved, 1 experimental)
Drugs by status
Phase 4 trials (1)
Phase 2 trials (2)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (17)
- Pfizer
- Regenera Pharma Ltd
- GenSight Biologics
- Quark Pharmaceuticals
- Huazhong University of Science and Technology
- Mahidol University
- Mashhad University of Medical Sciences
- McGill University
- University of Tehran
- Iran University of Medical Sciences
- Isfahan University
- Tabriz Medical University
- University of Paris
- Shiyan Taihe Hospital
- University of Grenoble
- Shiraz University
- People's Liberation Army of China
Organization Involved with Phase 2 Indications (10)
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (7)